No Data
No Data
No Data
Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
WARMINSTER, Pa., April 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a
Arbutus BiopharmaApr 18 00:00 ET
Arbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From Judge
A Delaware District Court sided with Arbutus Biopharma Corporation (NASDAQ:ABUS) and Genevant Sciences in their ongoing patent infringement case against Moderna Inc (NASDAQ:MRNA) COVID-19 vaccine.The
BenzingaApr 4 14:32 ET
Moderna Shares Slip Over Covid Vaccine Patent Dispute, But Chart Signals Potential Rebound Ahead
Moderna Inc (NASDAQ:MRNA) stock closed lower by 2.32% on Wednesday, as news around Arbutus Biopharma (NASDAQ:ABUS) impacted investor sentiment. Arbutus has received permission to pursue its patent inf
BenzingaApr 4 09:34 ET
Express News | JMP Securities Reiterates Market Outperform on Arbutus Biopharma, Maintains $4 Price Target
Moomoo 24/7Apr 4 08:49 ET
Unpleasant Surprises Could Be In Store For Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares
You may think that with a price-to-sales (or "P/S") ratio of 28.9x Arbutus Biopharma Corporation (NASDAQ:ABUS) is a stock to avoid completely, seeing as almost half of all the Biotechs companies in th
Simply Wall StApr 4 06:13 ET
Analysts Are Bullish on These Healthcare Stocks: Atossa Therapeutics (ATOS), Arbutus Biopharma (ABUS)
TipRanksApr 3 15:20 ET
Mcsnacks H TupackOP : No resistance